IL-MI-JACK
1.6.2022 17:12:06 CEST | Business Wire | Press release
Mi-Jack Products, the industry leader in Rubber Tired Gantry (RTG) Cranes, container handling machinery, and technology for port and intermodal facilities, has announced a successful acquisition of Yardeye GmbH, a Germany-based automation, collision avoidance, and work zone protection provider for the port and rail container industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005458/en/
Yardeye’s RFID and GNSS-based equipment, personnel Real Time Locating System (RTLS), and Collision Avoidance System (CAS) fit seamlessly into Mi-Jack's Mi-Star® technology platform, which provides everything from differential GPS automated steering and GPS inventory management to virtualized operations view and centralized fleet management.
Combining both companies’ skilled and experienced technology groups into one will facilitate continued innovation and excellence for automation, collision avoidance, and work zone protection within ports and intermodal terminals.
Aaron Newton, VP of Sales for Mi-Jack, said, “By bringing these two similar but unique technology platforms together, the port and intermodal industries will now have an end-to-end automation solution with superior redundancy, led by a company [Mi-Jack] that’s been rooted in the container handling business for over 65 years.”
According to Simon Fiera, VP of Technology at Mi-Jack, “We see Yardeye as a key component of integrating into an agnostic crane manufacturing base for the purposes of automation and work zone protection. We look forward to the innovations and efficiencies that will come from combining the skillsets and experiences of both the European and North American technology teams.”
With this expanded footprint, Mi-Jack brings its world class support and service to Yardeye customers in North America and will provide Mi-Star technology solutions to ports and terminals across Europe. Mi-Jack provides 24/7/365 service and parts support and has a vast network of highly trained technicians and solutions experts that service customers both in-person and virtually.
Stephan Trauth, Managing Director of Yardeye, said, “We are very proud to join the Mi-Jack group. The know-how of both companies will generate more advanced capabilities and synergies. Together, we will provide an automation portfolio that sets new standards in the rail container industry. The network from Mi-Jack in the North American market and especially their competence will add more value and innovative ideas for our customers. We look forward to this new chapter!”
Christian Augustin, Founder of Yardeye and managing director of indurad said, “The team has been growing Yardeye since 2017 from a concept to a company with a global impact serving the intermodal and container handling industry. We are very proud with what we have achieved, and we believe that together with Mi-Jack, Yardeye will continue its success story, for our customers as well as our employees. indurad and I will continue to focus our activities on radar technology for bulk material handling.”
About Mi-Jack
Mi-Jack is recognized worldwide as an industry leader and innovator in rubber-tired gantry (RTG) cranes and other products and solutions globally. Mi-Jack's Mi-Star suite of automation technology includes AccuSteer , AccuStack , AccuView , VehicleView , and AccuFleet . Mi-Star is installed on thousands of pieces of equipment throughout the world.
Corporate headquarters are in Hazel Crest, Illinois at an ISO 9001:2017 certified facility that produces Translift™ and Travelift® RTG’s now in use on six continents. The company maintains four regional operations headquarters and five sales offices. Mi-Jack is part of the Lanco Group of Companies . For more information, go to www.mi-jack.com .
About Yardeye
Yardeye GmbH (www.yardeye.com ) operates internationally with a focus on port automation and work zone protection in container terminals. By Yardeye’s unique GNSS, RFID, and collisional avoidance technology, terminals are able to identify and track cranes, vehicles, and personnel for efficient intermodal yard operations and work zone protection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005458/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom